产品名称 VE 822
产品货号 Axon 2452 CAS [1232416-25-9] MF C24H25N5O3SMW 463.55 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description Selective ATR inhibitor (IC50 values 0.019 µM, 2.6 µM, and 18.1 µM for ATR, ATM, and DNA-PK, respectively) with in vitro and in vivo activity that decreases maintenance of cell-cycle checkpoints and homologous recombination in irradiated cancer cells, and increases persistent DNA damage. VE822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine. References Certificates Categories Extra info E. Fokas et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012 Dec 6;3:e441. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology ATR p53-Tumor Suppression PI3K-Akt-mTOR DNA-damage Response EC 2.7.11.1 Selective ATR inhibitor that decreases survival of pancreatic cancer cells Chemical name 5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine Parent CAS No. [1232416-25-9] Order Size Unit Price Stock 10 mg €110.00 In Stock
产品价格 现货询价,电话:010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

VE 822

Based on 18 reference(s) in Google Scholar 9 10 18

Axon 2452

CAS [1232416-25-9]

MF C24H25N5O3S
MW 463.55

  • Purity: 99%
  • Soluble in 0.1N HCl(aq) and DMSO

VE 822

Description

Selective ATR inhibitor (IC50 values 0.019 µM, 2.6 µM, and 18.1 µM for ATR, ATM, and DNA-PK, respectively) with in vitro and in vivo activity that decreases maintenance of cell-cycle checkpoints and homologous recombination in irradiated cancer cells, and increases persistent DNA damage. VE822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine.
产品资料